Abstract
Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.
Keywords: Aldosterone, angiotensin, dyslipidemia, fibrates, hypertension, new-onset diabetes, prediabetes, statins.
Current Pharmaceutical Design
Title:How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Volume: 19 Issue: 21
Author(s): Vasilios Tsimihodimos, Matilda Florentin and Moses S. Elisaf
Affiliation:
Keywords: Aldosterone, angiotensin, dyslipidemia, fibrates, hypertension, new-onset diabetes, prediabetes, statins.
Abstract: Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.
Export Options
About this article
Cite this article as:
Tsimihodimos Vasilios, Florentin Matilda and S. Elisaf Moses, How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/ 10.2174/13816128113199990304
DOI https://dx.doi.org/ 10.2174/13816128113199990304 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Natural Compounds in Lung Cancer
Current Medicinal Chemistry Phosphoinositide 3-Kinase Gamma (PI3Kγ) Inhibitors for the Treatment of Inflammation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery Identifying Patterns in Signs and Symptoms Preceding the Clinical Diagnosis of Alzheimer’s Disease: Retrospective Medical Record Review Study and a Nested Case-control Design
Current Alzheimer Research Hypotensive Effects of the Triterpene Oleanolic Acid for Cardiovascular Prevention
Current Molecular Pharmacology Angiotensin II: Role in Skeletal Muscle Atrophy
Current Protein & Peptide Science Editorial [ Hot Topic: Modifying Cardiovascular Risk Factors: Novel Cardiovascular Targets for Treatment by Noninvasive Imaging Techniques (Executive Editors: Aurelio Leone and Luigi Landini) ]
Current Pharmaceutical Design Oxidative/Nitrosative Brain Damage in Stress: Possible Target for Neuropsychopharmacological Drugs
Current Medicinal Chemistry - Central Nervous System Agents Arterial Wall Structure and Dynamics in Type 2 Diabetes Mellitus Methodological Aspects and Pathophysiological Findings
Current Diabetes Reviews Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology Origin of Chiral Pharmacology Stereochemistry in Metalloprotease Inhibition
Mini-Reviews in Medicinal Chemistry Endocannabinoid Receptor Antagonists and Other Emerging Pharmacological Strategies for Weight Reduction
Current Drug Targets - Cardiovascular & Hematological Disorders Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension
Current Vascular Pharmacology Thioredoxin-1 is a Novel and Attractive Therapeutic Approach for Various Diseases Including Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets Resveratrol: A Therapeutic Approach to Neurodegenerative Diseases and Aging
Mini-Reviews in Organic Chemistry Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Synthesis and Binding Properties of New Endothelin Receptor Ligands
Letters in Drug Design & Discovery Flavonoids and Anthranquinones as Xanthine Oxidase and Monoamine Oxidase Inhibitors: A New Approach Towards Inflammation and Oxidative Stress
Current Topics in Medicinal Chemistry Phosphodiesterases (PDEs) from Snake Venoms: Therapeutic Applications
Protein & Peptide Letters Measurement of the Endogenous Adenosine Concentration in Humans In Vivo: Methodological Considerations
Current Drug Metabolism New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design